Health In Tech, Inc.
HITNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for HIT. That does not mean none is planned.
Get an email about HIT's next catalysts
Track Health In Tech (HIT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
MCS-2 15 mg/day
Lower Urinary Tract Symptoms
MCS-2
Lower Urinary Tract Symptoms
MCS®
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
MCS-2 15 mg/day | Phase 3 | Lower Urinary Tract Symptoms | - | - |
MCS-2 | Phase 3 | Lower Urinary Tract Symptoms | - | - |
MCS® | Phase 2 | Prostate Cancer | - | - |
heart failure diagnosis
1 drug in this indication
relapsed/refractory follicular lymphoma
1 drug in this indication
muscle repair and healing injuries
1 drug in this indication
breast cancer risk prediction
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Health In Tech, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Health In Tech, Inc.'s (HIT) pipeline across Phase 3, Phase 2. Its lead program is MCS-2 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Health In Tech, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Health In Tech, Inc. (HIT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HIT biotech catalysts?→
Add HIT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Health In Tech, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
